Petrelintide (development name ZP8396)[1] is an
amylin analogue dosed once weekly, developed by
Zealand Pharma for the treatment of type 2 diabetes and obesity.[2][3][4] Preclinical data suggests it may be more effective in combination with
semaglutide.[5]
^Olsen, Minna B.; HöVelmann, Ulrike; Griffin, Jon; Knudsen, Kim M.; Johansen, Thue; Kendall, David; Heise, Tim (20 June 2023). "92-LB: Safety, Tolerability, and Clinical Effects of ZP8396, a Novel Long-Acting Amylin Analog—A Single Ascending Dose Trial". Diabetes. 72 (Supplement_1).
doi:
10.2337/db23-92-LB.
Petrelintide (development name ZP8396)[1] is an
amylin analogue dosed once weekly, developed by
Zealand Pharma for the treatment of type 2 diabetes and obesity.[2][3][4] Preclinical data suggests it may be more effective in combination with
semaglutide.[5]
^Olsen, Minna B.; HöVelmann, Ulrike; Griffin, Jon; Knudsen, Kim M.; Johansen, Thue; Kendall, David; Heise, Tim (20 June 2023). "92-LB: Safety, Tolerability, and Clinical Effects of ZP8396, a Novel Long-Acting Amylin Analog—A Single Ascending Dose Trial". Diabetes. 72 (Supplement_1).
doi:
10.2337/db23-92-LB.